SCHEMBL6477010

SCHEMBL6477010

O=Cc1ccc(OCCn2c(=O)oc3ccccc32)cc1

nearest known ligand 0.66

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
TSHR P16473 5/20 0.66
RAB9A P51151 4/20 0.66
SMN1; SMN2 Q16637 3/20 0.66
ALDH1A1 P00352 4/20 0.64
NPSR1 Q6W5P4 4/20 0.64
L3MBTL1 Q9Y468 2/20 0.64
HPGD P15428 2/20 0.64
MAPT P10636 1/20 0.64
POLB P06746 2/20 0.58
TP53 P04637 2/20 0.54
KMT2A Q03164 2/20 0.54
MAPK1 P28482 3/20 0.51
LMNA P02545 1/20 0.51
USP2 O75604 1/20 0.50
HTT P42858 1/20 0.50
MEN1 O00255 1/20 0.49
NPC1 O15118 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7019446 0.83 RAB9A (0.61) TSHRRAB9ASMN1; SMN2ALDH1A1NPSR1
SCHEMBL6485663 0.83 RAB9A (0.61) TSHRRAB9ASMN1; SMN2ALDH1A1NPSR1
SCHEMBL6485660 0.83 RAB9A (0.61) TSHRRAB9ASMN1; SMN2ALDH1A1NPSR1
SCHEMBL6477256 0.81 KDM4E (0.47) TSHRRAB9ASMN1; SMN2ALDH1A1NPSR1
SCHEMBL6487606 0.81 SIGMAR1 (0.59) TSHRRAB9ASMN1; SMN2ALDH1A1NPSR1
SCHEMBL9534830 0.81 HPGD (0.58) TSHRRAB9ASMN1; SMN2ALDH1A1NPSR1
SCHEMBL6475863 0.79 L3MBTL1 (0.57) TSHRRAB9ASMN1; SMN2ALDH1A1NPSR1
SCHEMBL6476905 0.77 TSHR (0.62) TSHRRAB9ASMN1; SMN2ALDH1A1NPSR1
SCHEMBL9538453 0.75 MEN1 (0.49) TSHRRAB9ASMN1; SMN2ALDH1A1NPSR1
SCHEMBL14667448 0.75 ALDH1A1 (0.66) TSHRRAB9ASMN1; SMN2ALDH1A1NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6919362-B2 Heterocyclic derivatives, preparation method and pharmaceutical compositions containing same LES LABORATOIRES SERVIER (FR) 2005-07-19 US disclosed
EP-1252150-B1 HETEROCYCLIC DERIVATIVES, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME SERVIER LAB (FR) 2003-06-04 EP disclosed
US-20030040533-A1 Novel heterocyclic derivatives, preparation method and pharmaceutical compositions containing same LES LABORATOIRES SERVIER (FR) 2003-02-27 US disclosed
EP-1252150-A1 NOVEL HETEROCYCLIC DERIVATIVES, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME Les Laboratoires Servier (FR) 2002-10-30 EP disclosed
WO-2001057002-A1 NOVEL HETEROCYCLIC DERIVATIVES, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME LES LABORATOIRES SERVIER (FR) 2001-08-09 WO disclosed
EP-0555251-A1 THIAZOLIDINE DIONE DERIVATIVES BEECHAM GROUP plc (GB) 1993-08-18 EP disclosed
WO-1992007838-A1 THIAZOLIDINE DIONE DERIVATIVES BEECHAM GROUP PLC (GB) 1992-05-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030040533-A1 Novel heterocyclic derivatives, preparation method and pharmaceutical compositions containing same CYP2F1, CYP11B2, CYP4B1 TSHR 844/4885RAB9A 3361/4885SMN1; SMN2 1823/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.